Evidence map›Paper›PMID 33184451›Full record

ArticleScientific reports2020

Characterization of Affitin proteolytic digestion in biorelevant media and improvement of their stabilities via protein engineering.

Aurélie Loussouarn, Ghislaine Béhar, Frédéric Pecorari, Mikael Croyal, Axelle Renodon-Cornière

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Aurélie LoussouarnCRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Ghislaine BéharCRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Frédéric PecorariCRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. frederic.pecorari@univ-nantes.fr.
Mikael CroyalNUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, 44000, Nantes, France.
Axelle Renodon-CornièreCRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. axelle.renodon-corniere@univ-nantes.fr.
Centre National de la Recherche Scientifique · FRInserm · FRNantes Université · FRPhysioPathologie des Adaptations Nutritionnelles · FRUniversité d'Angers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Affitins are a novel class of small 7 kDa artificial proteins which can be used as antibody substitutes in therapeutic, diagnostic and biotechnological applications. One challenge for this type of protein agent is their behaviour in the context of oral administration. The digestive system is central, and biorelevant media have fast emerged as relevant and reliable tools for evaluating the bioavailability of drugs. This study describes, for the first time, the stability of Affitins under simulated gastric and intestinal digestion conditions. Affitins appear to be degraded into stable fragments in in vitro gastric medium. We identified cleavage sites generated by pepsin that were silenced by site-directed mutagenesis. This protein engineering allowed us to enhance Affitin properties. We showed that a mutant M1 containing a double mutation of amino acid residues 6 and 7 in H4 and C3 Affitins acquired a resistance against proteolytic digestion. In addition, these mutations were beneficial for target affinity, as well as for production yield. Finally, we found that the mutated residues kept or increased the important pH and temperature stabilities of Affitins. These improvements are particularly sought after in the development of engineered binding proteins for research tools, preclinical studies and clinical applications.

Indexed as

MutationBiological AvailabilityCrystallography, X-RayDrug StabilityHumansIntestinesModels, MolecularMutagenesis, Site-DirectedPepsin AProtein BindingProtein EngineeringProtein Structure, SecondaryProteolysisRecombinant ProteinsStomachPepsin ARecombinant Proteins

Identifiers

PMID33184451
PMCPMC7661517
OpenAlexW3103211325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.